Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

RPR's docetaxel now approved in 49 countries

Feb. 7, 1997

Another Isis antisense compound to enter clinic

Feb. 7, 1997

Isis previews antisense anticancer program

Feb. 7, 1997

Follow-up data reported for Amelorad

Feb. 7, 1997

Merck describes improved chemotherapeutic agents

Feb. 7, 1997

Whole-body hyperthermia therapy enters clinic for new indication

Feb. 6, 1997

Sugen's TK antagonist enters phase II

Feb. 6, 1997

Antitumor prodrugs for ADEPT from Pharmachemie

Feb. 6, 1997

ChiRex and Cell Therapeutics sign supply agreement

Feb. 5, 1997

GeneMedicine IND approved

Feb. 4, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...